The FDA letter ordered Pfizer's unit to correct the violations promptly. The agency's letter also says failure to do so may result in legal action including seizure and injunction. The letter also warned the company to contact CDER's (Center for Drug Evaluation and Research) Drug Shortages Staff immediately in case the company is considering an action that is likely to lead to disruption in the supply of products manufactured at the Meridian Medical Technologies facility. Mylan came under criticism and public outrage in 2016 for continually raising the price of EpiPens starting in 2009. In 2007, the wholesale price of two EpiPens was about $100; the price was about the same in 2009; but by July 2013, the price was about $265. The 400+ percent increase in the prices of EpiPens occurred as Mylan launched a marketing campaign to increase awareness of the dangers of anaphylaxis for people with severe allergies, such as bee stings and peanut allergies.